|Articles|April 15, 2003
- BioPharm International-04-01-2003
- Volume 16
- Issue 4
Getting Ready for Risk-Based GMPs
Author(s)Patrick Clinton
by Patrick Clinton, BioPharm International As FDA moves toward a new vision of GMP regulations, BioPharm International asked industry experts some key quextions: What form will risk-based GMPs take? What are the benefits and costs for biotech? Will the change really encourage innovation? And, most important, can FDA leaders get field inspectors to buy into the new approach?
Advertisement
Articles in this issue
over 22 years ago
Virus Inactivation in the 1990s and into the 21st Centuryover 22 years ago
GMP Issues: Breaking Groundover 22 years ago
Guest Editorial: Benchmarking Biotechover 22 years ago
Optimized Nutrient Additives for Fed-Batch Culturesover 22 years ago
Inside Washington: GMP Progress ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5